← All trials
NCT01014858
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2013
- Primary completion
- Sep 1, 2014
- Completion date
- May 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Newcastle UniversityLead sponsor
- University of CambridgeCollaborator
- University of ManchesterCollaborator
- University of BirminghamCollaborator
- Newcastle UniversityStudy chair
- University of LondonStudy director
- Cancer Research UKStudy director
- University of PennsylvaniaStudy director
- Cardiff UniversityStudy director
- University of ManchesterStudy director
- Lancashire Teaching Hospitals NHS Foundation TrustStudy director
- Bangor UniversityCollaborator
- Newcastle UniversityCollaborator
- University of LondonCollaborator
- Lancashire Teaching Hospitals NHS Foundation TrustCollaborator
- Newcastle UniversityStudy director
- University of CambridgeStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.